Stock Track | Hims & Hers Health Soars 5.09% in Pre-Market on Potential FDA Leadership Change and Weight-Loss Drug Partnerships

Stock Track

7 hours ago

Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.

The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.

Furthermore, market optimism around the company's weight-loss drug partnerships is fueling the rally. Hims & Hers has re-signed its cooperation agreement with Novo Nordisk and entered a new partnership with Eli Lilly in April, significantly expanding its weight-loss drug distribution capabilities as a direct-to-consumer telehealth platform. This expansion aligns with strong demand for GLP-1 medications, as evidenced by Novo Nordisk's robust quarterly sales performance that exceeded expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136746888"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136746888\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136746888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136746888","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.09% in Pre-Market on Potential FDA Leadership Change and Weight-Loss Drug Partnerships","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.</p><p>The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.</p><p>Furthermore, market optimism around the company's weight-loss drug partnerships is fueling the rally. Hims & Hers has re-signed its cooperation agreement with Novo Nordisk and entered a new partnership with Eli Lilly in April, significantly expanding its weight-loss drug distribution capabilities as a direct-to-consumer telehealth platform. This expansion aligns with strong demand for GLP-1 medications, as evidenced by Novo Nordisk's robust quarterly sales performance that exceeded expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.09% in Pre-Market on Potential FDA Leadership Change and Weight-Loss Drug Partnerships</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.09% in Pre-Market on Potential FDA Leadership Change and Weight-Loss Drug Partnerships\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.</p><p>The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.</p><p>Furthermore, market optimism around the company's weight-loss drug partnerships is fueling the rally. Hims & Hers has re-signed its cooperation agreement with Novo Nordisk and entered a new partnership with Eli Lilly in April, significantly expanding its weight-loss drug distribution capabilities as a direct-to-consumer telehealth platform. This expansion aligns with strong demand for GLP-1 medications, as evidenced by Novo Nordisk's robust quarterly sales performance that exceeded expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1136746888","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136746888","pubTimestamp":1778486747,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.The surge is primarily driven by reports of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|Hims&Hers Health盘前大涨5.09%，因潜在FDA领导层变动和减肥药合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.Furthermore, market optimism around the company's weight-loss drug partnerships is fueling the rally. Hims & Hers has re-signed its cooperation agreement with Novo Nordisk and entered a new partnership with Eli Lilly in April, significantly expanding its weight-loss drug distribution capabilities as a direct-to-consumer telehealth platform. This expansion aligns with strong demand for GLP-1 medications, as evidenced by Novo Nordisk's robust quarterly sales performance that exceeded expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}